New Molecule ‘AbLecs’ Overcomes Cancer’s Immune Evasion

Cancer immunotherapy has revolutionized treatment for many, but a important number of patients still don’t respond to existing therapies like checkpoint inhibitors. Researchers at MIT and Stanford University have uncovered a key reason for this resistance – a “sugar-coating” camouflage used by cancer cells – and developed a new molecule, AbLecs, to overcome it. This breakthrough promises to reawaken the immune system to fight tumors in patients who previously didn’t respond to treatment.

The Problem: Cancer’s Immune Camouflage

Cancer cells often evade the immune system by displaying specific proteins that act as “don’t eat me” signals. These signals, especially PD-L1, bind to receptors on immune cells, effectively putting the brakes on the immune response. Checkpoint inhibitors, like those targeting PD-1/PD-L1, release these brakes, allowing the immune system to attack. Though, many cancers develop resistance to these inhibitors.

The Role of Glycans

The new research reveals that cancer cells aren’t just relying on proteins like PD-L1. they also utilize a layer of sugar molecules, called glycans, to shield themselves from immune detection. These glycans physically cover the surface of cancer cells, hindering the ability of immune cells to recognize and bind to the tumor. This “sugar-coating” acts as an additional layer of camouflage, even when checkpoint inhibitors are present.

Introducing AbLecs: Breaking the Camouflage

AbLecs (short for “glycan blocking lectins”) is a novel molecule designed to specifically bind to these glycans, effectively stripping away the cancer cell’s camouflage. By blocking the glycans, AbLecs exposes the underlying cancer cells, making them visible to the immune system.

How AbLecs Works

• Glycan Binding: AbLecs directly binds to the sugar molecules (glycans) on the surface of cancer cells.
• Immune Cell Access: This binding removes the glycan shield, allowing immune cells to recognize and attach to the cancer cells.
• Immune Activation: With the camouflage removed,the immune system can launch a targeted attack against the tumor.

Experimental Results & Future Directions

In laboratory experiments, AbLecs successfully restored the effectiveness of checkpoint inhibitors in cancer cells that were previously resistant. The molecule demonstrated the ability to kill cancer cells and stimulate an immune response. Researchers observed accomplished tumor reduction in preclinical models.

Next Steps

the research team is now focused on refining AbLecs and preparing for clinical trials. Further studies will investigate the molecule’s effectiveness against various types of cancer and its potential for combination therapies. The goal is to bring this promising new treatment to patients who have not benefited from existing immunotherapies.

Key Takeaways

• Cancer cells use glycans as a camouflage to evade the immune system.
• AbLecs is a new molecule that blocks these glycans, exposing cancer cells to immune attack.
• AbLecs restored the effectiveness of checkpoint inhibitors in resistant cancer cells in lab tests.
• This research offers hope for patients who don’t respond to current immunotherapies.

FAQ

Q: What are checkpoint inhibitors?

A: Checkpoint inhibitors are drugs that release the brakes on the immune system, allowing it to attack cancer cells. They target proteins like PD-1 and PD-L1.

Q: How is AbLecs different from checkpoint inhibitors?

A: Checkpoint inhibitors work by blocking the signals that suppress the immune system. AbLecs works by removing the camouflage that prevents the immune system from recognizing cancer cells in the first place.They can potentially work together.

Q: When will AbLecs be available to patients?

A: AbLecs is still in the preclinical stage of development.Clinical trials are planned, but it will likely be several years before it is available to patients.

Source: MIT News